Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Stelara (Ustekinumab) receives FDA Approval for Treatment of Moderate to Severe Plaque Psoriasis with Four-Times-A-Year Maintenance Dosing
Inhibition of autoimmune encephalomyelitis by a tetracycline.
Cumulative review of thrombotic microangiopathy, thrombotic thrombocytopenic purpura and hemolytic uremic syndrome reports with SC interferon beta-1a.
Uncovering Cryptic Glycan Markers in Multiple Sclerosis (MS) and Experimental Autoimmune Encephalomyelitis (EAE).
Tamoxifen Promotes Axonal Preservation and Gait Locomotion Recovery after Spinal Cord Injury in Cats.
Evaluation of serum oxidant/antioxidant balance in multiple sclerosis.
Endogeneous Remyelination: Findings in Human Studies.
The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures.
Cbl-b-deficient mice express alterations in trafficking-related molecules but retain sensitivity to the multiple sclerosis therapeutic agent, FTY720.
Anti-JC virus seroprevalence in a Finnish MS cohort.
Suppression of Brain Mast Cells Degranulation Inhibits Microglial Activation and Central Nervous System Inflammation.
Serum and CSF measles antibody levels increase over time in patients with multiple sclerosis or clinically isolated syndrome.
Discovery of Biologically Active Oncologic and Immunologic Small Molecule Therapies using Zebrafish: Overview and Example of Modulation of T Cell Activation.
Dual role of Response gene to complement-32 in multiple sclerosis.
Glial contributions to neural function and disease.
Effects of the Anti-Multiple Sclerosis Immunomodulator Laquinimod on Anxiety and Depression in Rodent Behavioral Models.
Is multiple sclerosis a proresolution deficiency disorder?
Reliability of a cognitive endpoint for use in a multiple sclerosis pharmaceutical trial.
No quiet surrender: molecular guardians in multiple sclerosis brain.
Multiple sclerosis and pain.
Genetics of primary progressive multiple sclerosis.
MARINOL®
"Bright spotty lesions" on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis.
Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US.
An evidence-based review of natalizumab therapy in the management of Crohn's disease.

Pages